13 results
Eating disorders: Initial assessment in primary care #Management #PrimaryCare #Endo #EatingDisorders #Anorexia #Bulimia #Nervosa #BMJ
disorders: Initial assessment ... care #Management #PrimaryCare ... #Endo #EatingDisorders ... Bulimia #Nervosa #BMJ
Key Clinical Points for Rosacea #Management #Derm #PrimaryCare #Rosacea #Overview #TakeHome #NEJM
Key Clinical Points ... Rosacea #Management #Derm ... #PrimaryCare #Rosacea ... Overview #TakeHome #NEJM
Xanthomas in Familial Hypercholesterolemia #Clinical #PrimaryCare #Derm #Xanthomas #FamilialHypercholesterolemia #Hypercholesterolemia #NEJM
Hypercholesterolemia #Clinical ... #PrimaryCare #Derm ... Hypercholesterolemia #NEJM
Acanthosis Nigricans and Insulin Resistance - A 27-year-old woman presented with a 2-year history of acanthosis
Panels A and B) #Clinical ... #Derm #Endo #Acanthosis ... #Nigricans #NEJM
Panel A shows a patient with erythematotelangiectatic rosacea, in which diffuse erythema and telangiectasia are present
#Clinical #Derm ... #PrimaryCare #Rosacea ... #NEJM
Crusted Scabies - Physical examination now revealed a generalized erythematous and scaly rash with intense hyperkeratotic
mites (Panel C) #Clinical ... #Derm #PrimaryCare ... Scabies #Microscopy #NEJM
Severe Plantar Warts in an Immunocompromised Patient - A physical examination revealed exophytic warty growths on
#Clinical #Derm ... #PrimaryCare #Transplant ... Immunocompromised #Foot #NEJM
A pearlescent nodule with telangiectasia arising from the right nasal ala #Clinical #PrimaryCare #Derm #BasalCellCarcinoma #BasalCell
right nasal ala #Clinical ... #PrimaryCare #Derm ... BasalCellCarcinoma #BasalCell #BMJ
Insulin-Mediated Lipohypertrophy - Two painless, rubbery, hyperpigmented masses were noted near the umbilical area. The patient
#Clinical #Derm ... #Endo #PrimaryCare ... Lipohypertrophy #Insulin #NEJM
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis - Incidence of New Vertebral, Clinical,
New Vertebral, Clinical ... Fracture #EBM #PrimaryCare ... #Endo #IM #Romosozumab ... #Alendronate #NEJM